Skip to main content

Laura Jean Havrilesky, MD

Laura Havirlesky, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-0188
Email: havri001@mc.duke.edu

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer. The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women.

Education and Training

  • Residency, Obstetrics And Gynecology, Duke University, 1995 - 1999
  • M.D., Duke University, 1995

Research

I am interested in using health economic models to inform decisions related to gynecologic cancers. Specific models have addressed the decision to administer intraperitoneal chemotherapy for newly diagnosed advanced ovarian cancer following optimal cytoreduction, the choice of chemotherapy regimen for recurrent platinum-sensitive ovarian cancer, and the exploration of screening strategies for ovarian cancer.

The ovarian cancer screening model examines the effects of test cost, sensitivity, specificity, and screen frequency on ovarian cancer mortality, the lifetime false positive rate of testing, the positive predictive value of the test, and its cost effectiveness. This type of model is potentially useful in informing the design trials of novel screening tests for ovarian cancer. I am also conducting a prospective study to quantify the effects of screening for, diagnosis of, and treatment for ovarian cancer on the quality of life of women. 

Publications

Chino, F, Suneja, G, Moss, H, Zafar, SY, Havrilesky, L, and Chino, J. "Health Care Disparities in Cancer Patients Receiving Radiation: Changes in Insurance Status After Medicaid Expansion Under the Affordable Care Act. (Accepted)" May 2018.

Full Text

Davidson, BA, Ehrisman, J, Abbott, S, Harmon, Z, Secord, AA, Berchuck, A, Lee, PS, Valea, FA, Li, X, Havrilesky, LJ, and Hall, AHS. "Prospective Evaluation of Lymph Node Processing at Staging Surgery for High-grade Endometrial Cancer. (Accepted)" International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 37, no. 3 (May 2018): 252-255.

Full Text

Wright, JD, Havrilesky, LJ, Cohn, DE, Huang, Y, Rathbun, J, Rice, LW, Brown, CL, Alvarez, RD, and Ko, EM. "Estimating potential for savings for low risk endometrial cancer using the Endometrial Cancer Alternative Payment Model (ECAP): A companion paper to the Society of Gynecologic Oncology Report on the Endometrial Cancer Alternative Payment Model." Gynecologic oncology (March 2018). (Review)

Full Text

Moss, HA, Samimi, G, Havrilesky, LJ, Sherman, ME, and Myers, ER. "Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach." Genetic epidemiology 42, no. 1 (February 2018): 117-122.

Full Text

Foote, J, Lopez-Acevedo, M, Samsa, G, Lee, PS, Kamal, AH, Alvarez Secord, A, and Havrilesky, LJ. "Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals." International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 28, no. 2 (February 2018): 302-307.

Full Text

Moss, HA, Havrilesky, LJ, Zafar, SY, Suneja, G, and Chino, J. "Trends in Insurance Status Among Patients Diagnosed With Cancer Before and After Implementation of the Affordable Care Act." Journal of oncology practice 14, no. 2 (February 2018): e92-e102.

Full Text

Billingsley, CC, Cohn, DE, Crim, AK, Li, Q, O'Malley, DM, and Havrilesky, LJ. "Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis." Cancer Treatment and Research Communications 14 (January 1, 2018): 21-25.

Full Text

Moss, HA, and Havrilesky, LJ. "The use of patient-reported outcome tools in Gynecologic Oncology research, clinical practice, and value-based care." Gynecologic oncology 148, no. 1 (January 2018): 12-18. (Review)

Full Text

Foote, J, Secord, AA, Liang, M, Cohn, DE, Jewell, E, and Havrilesky, LJ. "ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer." Journal of oncology practice 13, no. 12 (December 2017): e1030-e1039.

Full Text

Berchuck, A, Secord, AA, Moss, HA, and Havrilesky, LJ. "Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35, no. 36 (December 2017): 3999-4002.

Full Text

Pages